BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials 2020;88:105889. [DOI: 10.1016/j.cct.2019.105889] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Huisman TM, Dieterich DT, Friedman SL. Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. J Exp Pharmacol 2021;13:329-38. [PMID: 33776490 DOI: 10.2147/JEP.S265286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab 2021;4:e00296. [PMID: 34505423 DOI: 10.1002/edm2.296] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract 2021;2021:6612892. [PMID: 34326871 DOI: 10.1155/2021/6612892] [Reference Citation Analysis]
5 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
6 Guan B, Tong J, Hao H, Yang Z, Chen K, Xu H, Wang A. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharmaceutica Sinica B 2021. [DOI: 10.1016/j.apsb.2021.12.011] [Reference Citation Analysis]
7 Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318:G554-G573. [PMID: 31984784 DOI: 10.1152/ajpgi.00223.2019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
8 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
9 Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol 2021;74:1442-54. [PMID: 33631228 DOI: 10.1016/j.jhep.2021.02.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Diaz Soto MP, Lim JK. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. Hepat Med 2020;12:115-23. [PMID: 32884369 DOI: 10.2147/HMER.S230613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
12 Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2021:S0168-8278(21)02155-3. [PMID: 34740705 DOI: 10.1016/j.jhep.2021.10.018] [Reference Citation Analysis]
13 Fiorucci S, Biagioli M, Baldoni M, Ricci P, Sepe V, Zampella A, Distrutti E. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opin Drug Discov 2021;:1-16. [PMID: 33849361 DOI: 10.1080/17460441.2021.1916465] [Reference Citation Analysis]
14 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ. New drugs for non-alcoholic steatohepatitis. Liver Int 2020;40 Suppl 1:96-101. [PMID: 32077615 DOI: 10.1111/liv.14354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
17 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
18 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
19 Xiao Y, Wang Y, Liu Y, Wang W, Tian X, Chen S, Lu Y, Du J, Cai W. A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis. Liver Int 2021;41:2117-31. [PMID: 33894097 DOI: 10.1111/liv.14906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput Struct Biotechnol J 2021;19:2148-59. [PMID: 33995909 DOI: 10.1016/j.csbj.2021.04.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 2020;21:953-67. [PMID: 32237916 DOI: 10.1080/14656566.2020.1744564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Li C, Yang J, Wang Y, Qi Y, Yang W, Li Y. Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Front Pharmacol 2020;11:1247. [PMID: 32982723 DOI: 10.3389/fphar.2020.01247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther 2021;15:3997-4009. [PMID: 34588764 DOI: 10.2147/DDDT.S315724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Chiang JYL, Ferrell JM. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Res 2020;4:47-63. [PMID: 34290896 DOI: 10.1016/j.livres.2020.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Shuvaev S, Akam E, Caravan P. Molecular MR Contrast Agents. Invest Radiol 2021;56:20-34. [PMID: 33074931 DOI: 10.1097/RLI.0000000000000731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
26 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Reference Citation Analysis]
27 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res 2021;82:101094. [PMID: 33636214 DOI: 10.1016/j.plipres.2021.101094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
29 Liu Y, Xiao Y, Chen S, Tian X, Wang W, Wang Y, Cai W. The Farnesoid X Receptor Agonist Tropifexor Prevents Liver Damage in Parenteral Nutrition-fed Neonatal Piglets. J Pediatr Gastroenterol Nutr 2021;73:e11-9. [PMID: 33783400 DOI: 10.1097/MPG.0000000000003135] [Reference Citation Analysis]
30 Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail 2021;8:789-98. [PMID: 33534958 DOI: 10.1002/ehf2.13222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Reference Citation Analysis]
32 Rao S, Yang X, Ohshiro K, Zaidi S, Wang Z, Shetty K, Xiang X, Hassan MI, Mohammad T, Latham PS, Nguyen BN, Wong L, Yu H, Al-Abed Y, Mishra B, Vacca M, Guenigault G, Allison MED, Vidal-Puig A, Benhammou JN, Alvarez M, Pajukanta P, Pisegna JR, Mishra L. β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. Sci Transl Med 2021;13:eabk2267. [PMID: 34910547 DOI: 10.1126/scitranslmed.abk2267] [Reference Citation Analysis]
33 Albhaisi SAM, Sanyal AJ. New drugs for NASH. Liver Int 2021;41 Suppl 1:112-8. [PMID: 34155794 DOI: 10.1111/liv.14844] [Reference Citation Analysis]
34 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2021. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Reference Citation Analysis]
35 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Reference Citation Analysis]
36 Okamoto M, Toyama M, Baba M. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;182:104902. [PMID: 32739404 DOI: 10.1016/j.antiviral.2020.104902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
37 Jiang L, Xiao D, Li Y, Dai S, Qu L, Chen X, Guo M, Wei H, Chen Y. Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. Biochem Biophys Res Commun 2021;534:1047-52. [PMID: 33121679 DOI: 10.1016/j.bbrc.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020;98:106175. [PMID: 33045403 DOI: 10.1016/j.cct.2020.106175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
40 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Doulberis M, Papadimitriou K, Papaefthymiou A, Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 2020;1:170-83. [DOI: 10.37349/emed.2020.00012] [Reference Citation Analysis]